Pregnancy
category C for Intranasal Bioavailability 0.51% (Intranasal) | Routes of
administration Intranasal | |
 | ||
AHFS/Drugs.com International Drug Names ATC code R01AD12 (WHO) R03BA09 (WHO) Legal status UK: POM (Prescription only)
US: ℞-only | ||
Fluticasone furoate is a synthetic corticosteroid derived from fluticasone, marketed by GlaxoSmithKline as Veramyst (US), Allermist (Japan, アラミスト) and Avamys (Australia, Canada, EU, South Africa, South America, Mexico, Israel, and South Korea) for the treatment of allergic rhinitis administered by a nasal spray.
The combination drug fluticasone furoate/vilanterol, marketed as Breo Ellipta (US, Canada) and Relvar Ellipta (UK), is approved for use in the United States by the Food and Drug Administration for long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. As of 2015, it is also approved for the treatment of asthma.
References
Fluticasone furoate Wikipedia(Text) CC BY-SA